-+ 0.00%
-+ 0.00%
-+ 0.00%

Benchmark Maintains Buy on Humacyte, Raises Price Target to $17

Benzinga·12/23/2024 14:21:18
Listen to the news
Benchmark analyst Bruce Jackson maintains Humacyte (NASDAQ:HUMA) with a Buy and raises the price target from $15 to $17.